key: cord-0914096-9qmqjzm9
authors: liu, Jia‐Mei; Tan, Bai‐Hong; Wu, Shuang; Gui, Yue; Suo, Jia‐Lei; Li, Yan‐Chao
title: Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement in the lethality of SARS‐CoV‐2 infection
date: 2020-10-01
journal: J Med Virol
DOI: 10.1002/jmv.26570
sha: 4d867882b6a6e5171f857c0fb4bb168ef221653e
doc_id: 914096
cord_uid: 9qmqjzm9

The outbreak of coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), has become a significant and urgent threat to the global health. This review provided strong support for CNS infection with SARS‐CoV‐2 and shed light on neurological mechanism underlying the lethality of SARS‐CoV‐2 infection. Among the published data, only 1.28% COVID‐19 patients who underwent cerebrospinal fluid (CSF) tests were positive to SARS‐CoV‐2 in CSF. However, this does not mean the absence of CNS infection in most COVID‐19 patients, because postmortem studies revealed that some patients with CNS infection showed negative results in CSF tests for SARS‐CoV‐2. Among 20 neuropathological studies reported so far, SARS‐CoV‐2 was detected in the brain of 58 cases in 9 studies, and three studies have provided sufficient details on the CNS infection in COVID‐19 patients. Almost all in vitro and in vivo experiments support the neuroinvasive potential of SARS‐CoV‐2. In infected animals, SARS‐CoV‐2 was found within neurons in different brain areas with a wide spectrum of neuropathology, consistent with the reported clinical symptoms in COVID‐19 patients. Several lines of evidence indicate that SARS‐CoV‐2 used hematopoietic route to enter the CNS. But more evidence supports the trans‐neuronal hypothesis. SARS‐CoV‐2 has been found to invade the brain via the olfactory, gustatory and trigeminal pathways, especially at the early stage of infection. Severe COVID‐19 patients with neurological deficits are at a higher risk of mortality, and only the infected animals showing neurological symptoms became dead, suggesting that neurological involvement may be one cause of death. This article is protected by copyright. All rights reserved.

encephalomyelitis, might be associated with systemic inflammatory response syndrome, sepsis, multi-organ failure, or post-infectious, immune-mediated complications 11 -12 . However, some neurological symptoms such as encephalitis and anosmia-hyposmia might be caused by direct invasion of the CNS by the virus. It is quite likely that the neurotropism of SARS-CoV-2 leads to the relatively high percentage of neurologic involvement.

In some COVID-19 patients, neurological manifestations were supported by abnormal changes of head computed tomography, magnetic resonance imaging, and/or electroencephalography. However, most neuroimaging findings reported only nonspecific imaging pattern, which could not provide a specific diagnosis. Moreover, the complex clinical course and long ICU stay of COVID-19 patients also acted as confounding factors. Therefore, a clear cause-effect relationship between SARS-CoV-2 infection and neuroimaging findings is difficult to establish in most cases in the absence of more specific detection 13 .

In this review, we assessed the so far documented evidence for SARS-CoV-2 neuroinvasion, mainly obtained from cerebrospinal fluid (CSF) tests, postmortem and experimental studies. Confirming the neuroinvasive potential of SARS-CoV-2 and clarifying the underlying mechanism are crucially important for understanding COVID-19 and its potential long-term sequelae.

An exhaustive search of case reports, cohort studies, series of cases, postmortem studies, animal models, and clinical trials related to the possible neuroinvasion of SARS-CoV-2 was performed through MEDLINE/PubMed and COVID-19-related preprints from medRxiv and bioRxiv from Dec 12, 2020 to Sep 14, 2020 . In addition, the references of relevant articles were also scanned for additional studies related to SARS-CoV-2 and CNS infection.

The papers on COVID-19 were retrieved by using "novel coronavirus disease 2019 or COVID 19 or severe acute respiratory syndrome coronavirus 2 or SARS CoV 2 or 2019 novel coronavirus or 2019 nCoV" in Title/Abstract (Strategy 1). To reveal the involvement of nervous system in COVID-19, the following key words in Title/Abstract were combined with Strategy 1: "neurological or nervous system or CNS or PNS or brain or cerebrum or cerebral or cerebellum or cerebellar or thalamus or thalamic or hippocampus or hippocampal or pons or pontes or pontine or brainstem or oblongata or medulla oblongata or spinal cord or cerebrospinal or neuron or nerve or neural or encephalitis or anosmia-hyposmia".

A piece of evidence for SARS-CoV-2 in the CSF was first reported by Moriguchi et al. in Japan on Mar 8, 2020 8 . In Yamanashi, Japan, a man aged 24 years had visited two separate clinics before a definite diagnosis in the affiliated hospital of Yamanashi University. This patient presented fatigue, fever and headache, but no abnormal changes of chest X-ray or blood tests. However, on the 9th day after the onset of illness, he became unconscious and developed transient generalized seizures. Brain imaging examinations confirmed him as a case of meningitis/encephalitis associated with SARS-CoV-2 infection. Although polymerase chain reaction (PCR) was negative in the nasopharyngeal swab, SARS-CoV-2 RNA has been demonstrated in the CSF 8 .

A parallel study of concomitant encephalitis was reported for a male patient aged 56 years on Mar 16, 2020 in Beijing Ditan Hospital, China 14 . Similarly, PCR test of SARS-CoV-2 was positive in the CNS.

In a case study published on Apr 17, Duong et al. were still unable to send CSF specimen for PCR testing through local commercial, government or academic laboratories by the day of the writeup submission (day 9 after admission) 6 . However, in an update to this article on May 6, 2020, the CSF of this patient was subsequently found to be positive for SARS-CoV-2 on RT-PCR 15 . Of note, SARS-CoV-2 infection in this case was entirely confined to the CNS, with no involvement of other organ systems.

On Jun 3, Färber et al. reported a young male infant admitted to the emergency department with apparent acute sepsis 16 . CSF testing initially showed no infection but then SARS-CoV-2 w as detected in the lower pharynx and CSF.

On Jun 16, 2020, Kremer et al. reported a retrospective study of 40 COVID-19 17 . Among 28 patients who underwent CSF examination, only one patient was positive for SARS-CoV-2 RNA in the CSF. This article is protected by copyright. All rights reserved.

On Jun 20, Domingues et al. reported a patient with mild respiratory symptoms and neurological manifestations compatible with clinically isolated syndrome 18 . The viral genome of SARS-COV-2 was detected and sequenced in the CSF with 99.74-100% similarity between the patient virus and worldwide sequences.

On Jun 26, Westhoff et al. reported a 69-year old man, who suffered from COVID-19 pneumonia, meningoencephalitis and nephritis 19 . RT-PCR test was positive for SARS-CoV-2 in the CSF and the biopsy specimens from kidneys. Of note, the detection of SARS-CoV-2 was negative in blood samples, and therefore a false positive finding caused by perfusion with the infected blood is unlikely.

On Jul 23, Mardani et al. described a 64-year-old woman with COVID-19-induced respiratory distress whose treatment resulted in a negative nasopharyngeal swab RT-PCR result for SARS-CoV-2 20 . However, after a few weeks, relapse occurred, as indicated by symptoms of acute meningoencephalitis. RT-PCR test for SARS-CoV-2 became positive in her CSF, nasopharyngeal and tracheal aspiration specimens.

On Jul 31, Fadakar et al. reported a 47-year-old male who suffered from progressive vertigo and ataxia for 7 days prior to admission 21 . Neurological examination revealed cerebellar dysfunction, and brain MRI depicted edema of the cerebellar hemisphere associated with leptomeningeal enhancement. CSF analysis showed mild lymphocytic pleocytosis, elevated protein, and lactate dehydrogenase. SARS-CoV-2 RNA was detected in the oropharyngeal/nasopharyngeal and CSF specimens.

On Aug 8, Helms et al. conducted a bicentric cohort study of 150 COVID-19 patients with acute respiratory distress syndrome between Mar 3 and May 5, 2020 22 . CSF examination revealed inflammatory disturbances in 18 out of 28 patients, and RT-PCR of SARS-CoV-2 was positive in one patient (1/28).

On Aug 11, Cebrián et al. described a 74-year-old woman with gastrointestinal manifestations followed by headache and impaired consciousness 23 . This patient did not develop fever, cough, anosmia, hypogeusia, or respiratory symptoms. Neurological examination revealed impaired consciousness, photophobic appearance, confusion and incoherent speech. Notably, both nasopharyngeal and CSF qRT-PCR tests were positive for SARS-CoV-2.

On Sep 8, Virhammar et al. reported a case of COVID-19-related acute necrotizing encephalopathy. SARS-CoV-2 RNA was found in CSF 19 days after symptom onset after testing negative twice 24 . Although monocytes and protein levels in CSF were only marginally increased, this patient never experienced a hyperinflammatory state. Moreover, extremely high concentrations of neurofilament light chain protein, glial fibrillary acidic protein, and tau, were detected in the CSF. This article is protected by copyright. All rights reserved.

On Sep 14, Khodamoradi et al. reported a 49-year-old woman who presented COVID-19 meningitis, but without pulmonary involvement or brain MRI changes 25 Of note, on Jun 11, Destras et al. reported a large retrospective systematic screening of 578 CSF samples, corresponding to 555 patients, received during the outbreak in Lyon from Feb 1 to May 11, 2020 28 . Only two post-mortem CSF samples from two COVID-19 patients were slightly positive for SARS-CoV-2. For one patient, a blood sample was available and was positive for SARS-CoV-2 whereas brain biopsy samples from the two patients were both negative, suggesting contamination of the CSF by blood. These data suggest that SARS-CoV-2 tests in CSF are not relevant in the general population.

Espíndola et al. suggested that the patients with COVID-19 displaying distinct neurological disorders might have extremely low levels of SARS-CoV-2 RNA in the CSF, because the immune clearance of viruses from the CSF might be prior to the neurological manifestations 29 . Thus, the detection of SARS-CoV-2 in CSF may depend on disease severity, the time of sample collection or the sensitivity of the molecular test used.

Supporting this, Wang et al. report a 68-year-old COVID-19 man with serious neurological damage and mental abnormalities, whose CSF test showed negative result 30 . However, IgM and IgG antibodies against SARS-CoV-2 were 100 times higher in the CSF than in the serum.

Similarly, Lu et al. reported a case of SARS-CoV-2 infection with manic-like symptoms 31 . After manic-like attack, IgG antibody specific to SARS-CoV-2 was detected in the CSF, but RT-PCR in CSF for the SARS-CoV-2 was negative.

In a preprint recently deposited in bioRxiv, Song et al. reported detection of IgG antibodies specific to the spike protein of SARS-CoV-2 in CSF from a COVID-19 patient with acute encephalopathy 32 . The antibodies were able to block SARS-CoV-2 infection in brain organoids, which highlights the potential of SARS-CoV-2 neuroinvasion and subsequent immune response in the CNS.

Of note, CSF examination is not consistently available, even if in some cases CSF has been obtained 6, 31, 33 . Although CSF detection of SARS-CoV-2 was unavailable or negative in some cases, concomitant neurological symptoms have been remarkably This article is protected by copyright. All rights reserved.

improved after the SARS-CoV-2 nucleic acid test became negative in the nasopharyngeal swab 5, 26, 34 .

Up to Sep 14, 2020, a total of 20 autopsy studies on neuropathology were retrieved, among which CNS detection of SARS-CoV-2 was negative in 12 (out of 12) cases from 3 studies 36, 42, 43 , and positive in 58 (out of 87) cases (66.7%) from 9 studies 46 -54 , and unavailable for 109 cases in 8 studies 35, 37 -41, 44, 45 .

Among these studies, two did not describe neuropathological findings, since autopsy of the brain was not their main focus 35, 36 . One study reported acute hemorrhagic necrotizing encephalitis and acute disseminated encephalomyelitis-like changes in a patient who died from complications of COVID-19 37 . In two studies, brain autopsy revealed only vascular injury 38, 39 . Another study used ultrasound-guided minimally invasive autopsy, and found reactive gliosis in 8 (89%) patients, neuronal satellitosis in 5 (55.5%), small vessels disease 3 (33.3%), and perivascular haemorrhages in 1 (11.1%) patient 40 . However, none of these studies carried out detection of SARS-CoV-2 in the brain.

Of note, on May 21, 2020, Schaller et al. reported a series of 10 autopsies 41 . They found no signs of encephalitis or CNS vasculitis. Brain remained unaffected in the 10 patients with severe critical COVID-19. In this study, detection for SARS-CoV-2 was not performed.

On Aug 6, Kantonen et al. reported an autopsy study on 2 COVID-19 patients 42 . No signs of encephalitis or meningitis were detected in any patients. In one patient, they found severe ischemic injury, abundant microhemorrhages and enlarged perivascular spaces most pronounced in the white matter and deep gray matter. A few small perivascular white matter lesions, with macrophages engulfing myelin, were also reported. Of note, RT-PCR and immunostaining could not demonstrate in the two patients marked injury or presence of SARS-CoV2 in the olfactory epithelium, olfactory bulbs, or brainstem.

On Sep 8, 2020, Jensen et al. reported neuropathological findings in 2 patients with fatal COVID-19 43 . The first case showed pathological changes consistent with severe multi-territorial cerebral vascular injury. In the second case, however, they found brainstem encephalitis centered on the dorsal medulla and subacute regional infarct involving cerebellar cortex. In the dorsal medulla, there was a moderate parenchymal infiltrate of T-lymphocytes with neuronophagia, and activated microglia forming microglial nodules. However, in situ hybridization and RT-PCR for SARS-CoV-2 RNA were negative in tissue sampled from the area of pathology. This article is protected by copyright. All rights reserved.

A total of 14 COVIID patients were included in the three autopsy studies mentioned above. Detection of SARS-CoV-2 by RT-PCR and/or immunostaining was performed in two studies, but the results did not support the infection of CNS in 4 COVID-19 patients 42, 43 .

On May 13, Bulfamante et al. reported an ultrastructural investigation of postmortem samples from a COVID-19 patient who died from SARS-CoV-2 infection 44 . This patient was admitted with fever, anosmia, dysgeusia, headache, a possible seizure, and acute respiratory failure. Ultrastructural autopsy performed within 3 hours from death demonstrated severe and widespread damage in olfactory nerve, gyrus rectus and medulla oblongata. The damage involving neurons, glia, nerve axons, and myelin sheath was progressively less severe from the olfactory nerve to gyrus rectus and to the brainstem.

On Jun 20, von Weyhern et al. carried out an autopsy study on 6 patients, who died from COVID-19 in April, 2020 45 . Surprisingly, this study did not observed conspicuous CNS endotheliitis. In all brain samples from 4 cases, wide neuronal cell loss and axon degeneration have been seen in the brainstem, including the dorsal motor nuclei of vagus nerve, nucleus tractus solitarii, dorsal raphe nuclei, and fasciculus longitudinalis medialis. In addition, localized perivascular and interstitial infiltration of immune cells have also been found in the brain.

In the two studies, specific neuropathological findings have been observed in 5 COVID-19 patients 44, 45 , which could not be attributed to only severe hypoxia observed in critical COVID-19 cases. However, further detection of SARS-CoV-2 was not performed in the brain.

On June 12, 2020, Solomon et al. reported autopsy findings from 18 patients who died from SARS-CoV-2 infection between April 14 and April 29, 2020 46 . They found only hypoxic changes, but no encephalitis or other specific brain changes in these patients. qRT-PCR tests in 32 sections from 16 patients including 3 sections from the medulla and 3 sections from the frontal lobes and olfactory nerves were positive to SARS-CoV-2 nucleocapsid protein.

On Aug 12, Remmelink et al. carried out a postmortem study on 17 adult patients with COVID19, who died from respiratory failure or multiple organ failure 47 . They found 8 cases with cerebral hemorrhage or hemorrhagic suffusion, 3 with focal ischemic necrosis, 5 with edema and/or vascular congestion and 10 with diffuse or focal spongiosis. SARS-CoV-2 RNA has been found in 9 of 11 cerebral samples.

On Aug 26, Al-Dalahmah et al. reported an autopsy study of one COVID-19 patient, which was performed 3 h after death 48 . They found cerebellar hemorrhage and acute infarcts in the dorsal pons and medulla, but no evidence of vasculitis. Remarkably, there This article is protected by copyright. All rights reserved.

were microglial nodules and neuronophagia bilaterally in the inferior olives and multifocally in the cerebellar dentate nuclei. PCR tests for SARS-CoV-2 demonstrated the presence of viral transcripts in the nasal epithelium and cerebellar clot, low levels in the olfactory bulb and cerebellum, but no detectable transcripts in the medulla.

In the studies reported by Solomon et al. 46 and by Al-Dalahmah et al. 48 , the positive PCR results for SARS-CoV-2 in the CNS did not be confirmed in the same brain areas by immunostaining or in situ hybridization. In the study of Remmelink et al. 47 , although SARS-CoV-2 RNA was found in 9 of 11 cerebral samples, autopsy examination did not found evidence of viral encephalitis or vasculitis. These discrepancies raised the question whether the positive PCR tests were false or not. 

SARS-CoV-2 copies per cell were detected in the respiratory tract, and lower levels were detected the kidneys, liver, heart, brain, and blood. Of 22 patients, 8 patients showed positive PCR results for SARS-CoV-2 in the brain. Brain tropism seemed to increase with the number of coexisting conditions. These findings indicate a broad organotropism of SARS-CoV-2.

On Aug 20, Hanley et al. carried out a postmortem study on 10 COVID-19 patients between Mar 1 and Apr 30, 2020 53 . In addition to ischaemic changes in the cortex and white matter, moderate to intense microglial activation was the most prominent pathological feature in the CNS ( Among the six studies, PCR, immunochemical, and ultrastructural techniques have been used to detect whether SARS-CoV-2 was present in the brain. In three studies, the presence of SARS-CoV-2 in the brain was confirmed at least by two different methods 49 -51 . These studies have provided strong evidence for the CNS infection in COVID-19 patients.

Taken together, autopsies of the brain have provided distinctly different pathologies in COVID-19 patients. This is probably due to the fact that, although the patients with COVID-19 who underwent neuropathological analysis all showed signs of CNS involvement, they had different neurological features and probably different neurological diseases. Even so, autopsy evidence has emerged supporting the direct invasion of SARS-CoV-2 in the CNS, at least in some COVID-19 patients.

Up to Sep 14, we retrieved a total of 13 experimental articles relevant to SARS-CoV-2 neuroinvasion, including 4 in vitro and 9 in vivo studies. Among them, one in vitro study reported only the effects of SARS-CoV-2 infection on blood brain barrier This article is protected by copyright. All rights reserved.

Thereafter, Ramani et al. reported that SARS-CoV-2 could enter 3D human brain organoids within two days of exposure, where it preferably targeted the neurons 56 . SARS-CoV-2 infection induced altered distribution of Tau from axons to soma, hyperphosphorylation, and apparent neuronal death.

Song et al. analyzed the neuroinvasive potential of SARS-CoV-2 in the hiPSC-derived forebrain-specific human neural progenitor cells 32 . Similar to the findings reported by Bullen et al. 55 , they observed infection of neuronal cells in 9-week-old organoids as early as 24 h post infection, with significantly increased number of SARS-CoV-2 positive cells at 96 h. The majority of SARS-CoV-2 infected cells were localized within MAP2-positive cellular fields of mature neurons. Electron microscopic observations showed that the virus could utilize host cell machinery to replicate in the neurons. In addition, SARS-CoV-2 infection has been found radial glia and neuronal progenitor cells.

To clarify the pathophysiology of COVID-19, several animal models for SARS-CoV-2 infection have been developed. In Golden Syrian hamsters, SARS-CoV-2 RNA was detected in many extrapulmonary tissues such as liver, heart, spleen, kidneys, brain, and salivary glands 57 . In rhesus macaques, viral replication was observed in gut, bladder, heart, skeletal muscles and spinal cord 58 . These findings are well consistent with the extrapulmonary manifestations in COVID-19 patients.

SARS-CoV-2 hACE2 transgenic mouse model has also been successfully developed by several research groups, respectively 59, 60 . In a study reported by Sun et al. 59 , robust viral RNA replication of SARS-CoV-2 was found in lungs, trachea, and brain tissues in the infected mice after intranasal inoculation. Furthermore, immunostaining of brain sections demonstrated robust viral S protein expression in neurons, astrocytes and microglial cells 59 .

In a study reported by Jiang et al. 60 , 4 out of 14 infected mice showed noticeable respiratory distress and neurological symptoms from 2 days after infection. SARS-CoV-2 genomic sequences have been isolated from the lung and brain tissues in these mice.

Similarly, Rathnasinghe et al. reported that B6 K18-hACE2 mice intranasally infected with SARS-CoV-2 showed high viral titers in the lung at day 2 post-infection, and some animals had the virus in the brain 61 . By day 5 post-infection viral titers in the lung were reduced while titers in the brain had increased.

Using K18-hACE2 mice, Zheng et al. found that the predominant target organs were the lung at early time points, and variably, the brain at later time points 62 . In some, but not all animals, the brain tissue titers gradually increased from 2 to 6 postinfection. Immunostaining against the viral N at 6 days postinfection revealed extensive staining in several brain regions including olfactory bulb, cerebral cortex, caudate/putamen, This article is protected by copyright. All rights reserved.

thalamus, hypothalamus, and ventral striatum, In addition, the area postrema and hypoglossal nucleus were also infected.

Golden et al. evaluated the pathogenesis of SARS-CoV-2 in mice expressing the human ACE2 gene under the control of the keratin 18 promotor 63 . Brain infection was not observed in the majority of animals examined on day 3, but was prevalent in mice necropsied on days [5] [6] [7] [8] [9] [10] [11] . Evidence of SARS-CoV-2 was found throughout the brain including the thalamus, hypothalamus, amygdala, cerebral cortex, medulla, pons and midbrain. Viral spike protein was detected in NeuN positive cells, indicating viral infection of neurons. Viral antigen was absent in GFAP positive cells suggesting this virus does not productively infect astrocytes. In the thalamus/hypothalamus, vasculitis was the most common lesion characterized by endothelial hypertrophy and increases in mononuclear leukocytes within the vessel wall and/or filling the perivascular space. However, cells within the vessel walls and perivascular spaces were negative for viral genomic RNA.

Moreover, two experimental papers about SARS-CoV-2 infection were deposited in bioRxiv in August 2020. By using transgenic mice expressing K18-hACE2, Yinda et al. reported that SARS-COV-2 could enter cerebral cortex and hippocampus after intranasal inoculation 64 . In these regions, SARS-CoV-2 antigen was present in neurons and glial cells along the soma and axons of infected neurons.

By using deer mice, whose ACE2 receptor shares 17 of the 20 critical residues for SARS-CoV-2 binding, Fagre et al. demonstrated robust virus replication in respiratory, digestive and nervous systems after intranasal inoculation 65 . Of interest, the glomerular layer of main olfactory bulb became spongiotic and immunoreactive at 3 post inoculation, where SARS-CoV-2 antigen was detected in the cytoplasm of mitral and microglial cells. Less severe glial reactions and immunoreactivity were also found within brainstem, where the presence of SARS-CoV-2 was found multifocally at the level of lateral sulcus nucleus, optic chiasm, hypothalamus, thalamic parabrachial nucleus, and ventral posteromedial nucleus culminating in the gustatory cortex. In addition, this study shows that SARS-CoV-2 might invade the brain via retrograde axonal transmission along gustatory, olfactory and trigeminal pathways at the early stage of infection.

Taken together, in vitro studies show that SARS-CoV-2 cannot only enter and replicate in neuronal cells, but also infect many other cells in nerve tissue including radial glia and neuronal progenitor cells 32, 55, 56 . In addition, the in vitro findings have provided initial insights into the potential neurotoxic effect of SARS-CoV-2.

The results obtained from animal experiments are generally consistent with each other in terms of neuronal infection, but there are some discrepancies in whether glial cells are infected, which may be due to the different animal sources or virus strains they used. Animal experiments have demonstrated that SARS-CoV-2 does possess a This article is protected by copyright. All rights reserved.

neuroinvasive potential similar to its counterpart, SARS-CoV 57-60, 64, 65 . Importantly, the in vivo findings show that CNS involvement may contribute to the lethality of SARS-CoV-2 infection.

In this review, we have assessed the so far documented evidence for SARS-CoV-2 neuroinvasion, which points out a non-negligible involvement of CNS in the pathophysiology of COVID-19. These data does not only end the debate about the neuroinvasive potential of SARS-CoV-2, but has also begun to unravel the mechanisms underlying the lethality of SARS-CoV-2 infection.

So far, the presence of SARS-CoV-2 in CSF was reported in at least 13 COVID-19 patients. However, more than 1000 COVID-19 patients who underwent CSF tests showed negative results. The positive detection of SARS-CoV-2 in CSF was only 1.28% among the pooled cases.

Several postmortem studies showed that despite the presence of SARS-CoV-2 in the brain parenchyma of some patients, RT-PCR tests for SARS-CoV-2 were negative in their CSF 49, 54 . This indicates that negative outcomes of PCR tests in CSF do not mean the absence of SARS-CoV-2 in the CNS. Therefore, CSF test is not a reliable method to reveal whether the CNS is infected or not.

Not all postmortem studies on neuropathology reported the presence of SARS-CoV-2 in the brain. Among the published autopsy studies, brain detection of SARS-CoV-2 was positive in 58 (out of 87) cases in 9 studies, but only three have provided sufficient details on the CNS infection in 19 decreased patients with COVID-19 49 -52 .

Most autopsies provided insufficient details, which may reflect the challenge of studying such patients. As a matter of fact, complete brain removal was difficult or even not allowed in some studies 40, 47 . Since neurotropic viruses infect only specific brain areas related to their entry routes, incomplete or random sampling is not suitable for the study of CNS infection.

On the other side, almost all in vitro and in vivo experiments support the neuroinvasive potential of SARS-CoV-2. In culture conditions, SARS-CoV-2 predominantly targeted and replicated in neuronal cells 32, 55, 56 , and induced altered distribution of Tau from axons to soma, hyperphosphorylation, and apparent neuronal death 56 .

As compared to postmortem studies, animal experiments have provided detailed information on the neuroinvasive potential of SARS-CoV-2 60, 61, 59, 63 -65 , which revealed that the predominant target organs were the lung of infected animals at early time points, This article is protected by copyright. All rights reserved.

and variably, the brain at later time points 62, 63 . The presence of virus in CNS was found within neurons in different brain areas with a wide spectrum of neuropathology, well consistent with the reported clinical symptoms in COVID-19 patients 65 . Not all infected animals showed neurological symptoms or CNS infection 60, 61 , which may partially interpret negative detection of SARS-CoV-2 in some COVID-19 patients As many other animal models, the experimental results from animal models of SARS-CoV-2 infection cannot be simply generalized to human beings. In COVID-19 patients, different ages, underlying comorbidities, complex clinical course, and long ICU stay may all act as confounding factors. Although the patients with COVID-19 all showed signs of CNS involvement, they had different neurological features and probably different neurological diseases.

Nevertheless, the experimental results from animal models are generally consistent with those reported in some postmortem studies on COVID-19 patients. These findings not only provide undisputable evidence for SARS-CoV-2 neuroinvasion, but also shed light on the neurological mechanism of COVID-19.

SARS-CoV-2 can affect the CNS through direct routes-haematogenous and trans-neuronal pathways and also by indirect mechanisms which include cytokine dysregulation, peripheral immune cell transmigration, neuroinflammation, postinfectious autoimmunity, hypercoagulability, etc 66 .

As pointed out by some authors 67 , the finding of viral genome in CSF does not always indicate that SARS-CoV-2 can invade the brain via hematopoietic or trans-neuronal pathway. In the nasal epithelium, between the olfactory neurons and olfactory ensheathing cells which surround the olfactory neurons there exists a direct channel connecting the nasal cavity and the CSF surrounding the olfactory bulbs. This channel has been suggested as a trans-cribrial route for SARS-CoV-2 invasion 68 . In addition, the presence of SARS-CoV-2 in the CSF may be due to the anatomical connection between CNS lymphatic system and peripheral lymphatic vessels 67 . These speculations are theoretically possible, but supporting evidence is still lacking.

Cantuti-Castelvetri et al. found that SARS-CoV-2 could infect endothelial cells in small capillaries and medium-sized vessels in the olfactory bulb and tracts 51 . Moreover, SARS-CoV-2 viral particles have been ultrastructurally demonstrated in capillary endothelial cells in the frontal cortex 49 . These findings provide evidence supporting that SARS-CoV-2 may enter the CNS via the hematopoietic route.

Buzhdygan et al. found that SARS-CoV-2 spike protein could trigger a pro-inflammatory response on brain endothelial cells that may contribute to an altered This article is protected by copyright. All rights reserved.

state of BBB function 69 . In an in vivo study, Perrin et al. found that serum levels of the astroglial marker, S100B protein, were increased at the time of cytokine release syndrome in COVID-19 patient, reflecting an increased permeability of the BBB 70 . These findings indicate that SARS-CoV-2 may also invade the CNS by impaired BBB.

More evidence from clinical, autopsy and animal studies supports the trans-neuronal hypothesis. SARS-CoV-2 viral antigen has been demonstrated in the olfactory bulb and tracts 51 , and the damage in the olfactory pathway was progressively less severe from peripherally to centrally 44 . Moreover, MRI examinations of COVID-19 patients revealed obvious structural changes in the olfactory pathway including olfactory nerve, olfactory bulb and olfactory cortex, indicating that SARS-CoV-2 might enter the CNS via an olfactory bulb-mediated trans-neuronal route 31, 71, 72 .

The trans-neuronal hypothesis is also supported by animal experiments, where immunostaining against SARS-CoV-2 revealed extensive staining in many secondary or tertiary brain regions connected with the olfactory bulb 62, 65 . In addition, the results from animal experiments show that SARS-CoV-2 might invade the brain retrogradely along gustatory and trigeminal pathways at the early stage of infection 65 .

So far, the contribution of neurological involvement to mortality is still ill-defined in the infection with SARS-CoV-2. It is generally accepted that old age, underlying comorbidities, complex clinical course and long ICU stay all contribute to clinical deterioration and a higher mortality rate.

To reveal the risk factors of deaths caused by SARS-CoV-2 infection, Zou et al. analyzed clinical data of 121 COVID-19 patients from Jan 30, 2019, to Mar 23, 2020 73 . They found that severe cases and death of COVID-19 were associated with older age, comorbidities, organ dysfunction, lymphopenia, high cytokines, and weak immune responses.

von Weyhern et al. carried out an autopsy study on 6 patients who died from COVID-19 in April, 2020 45 . They found that patients older than 65 years with multiple comorbidities died from cardiorespiratory failure, while the younger died either from massive intracranial haemorrhage or pulmonary embolism.

Of interest, the patients with COVID-19 requiring ICU admission due to neurological issues, or those in ICU who manifested neurological deficits, are at a higher risk of mortality 74 . Moreover, COVID-19 patients who have recovered from their respiratory symptoms were found to be potentially at higher risk for long-term residual neuropsychiatric and neurocognitive conditions including depression, obsessive compulsive disorder, psychosis, Parkinson's disease and Alzheimer's disease 75 .

In an animal study reported by Jiang et al. 60 , 4 out of 14 infected mice showed noticeable respiratory distress and neurological symptoms from 2 days after infection. Only the mice showing neurological symptoms became dead, suggesting that neurological involvement may be one cause of death.

Song et al. further investigated the consequence of CNS involvement in SARS-CoV-2 infection by using transgenic mice overexpressing hACE2 32 . They found that the mice expressing hACE2 in the brains showed significant weight loss and death after either intranasal or intraventricular inoculation, even at the extremely low challenge virus dose. In contrast, the mice expressing hACE2 in lungs showed signs of lung pathology after intranasal inoculation, but no weight loss or death. The study highlights the possible lethal consequence of SARS-CoV-2 neruoinvasion in COVID-19 patients.

Among the COVID-19 patients with dyspnea, more than half needed intensive care 76, 77 . Many critical patients failed early attempts at weaning from invasive mechanical ventilation so that the time of ICU stay appears to be long 78 -79 . This is surprising since most of them had recovered from pneumonia. Further clinical evaluation of these patients indicated an involvement of brainstem and especially of the respiratory center 80 .

Consistent with this, at least 3 autopsy studies have described brainstem abnormalities after SARS-CoV-2 infection 43 -45 . Brainstem infection with SARS-CoV-2 was also reported in an animal experiment, where viral antigen was present multifocally at the level of lateral sulcus nucleus, optic chiasm, hypothalamus, thalamic parabrachial nucleus, and ventral posteromedial nucleus culminating in the gustatory cortex 65 .

Once in the CNS, SARS-CoV-2 will enter and replicate in neurons, leading to cell death. Infection of some brain areas, especially the brainstem, may lead to cardiorespiratory dysfunction and even death. The invasion of viruses and the death of neurons will subsequently activate astrocytes and microglia, inducing inflammatory reaction, which, together with intense cytokine release during florid cytokine storm, may make blood-brain barrier more permeable, thereby facilitating entry of SARS-CoV-2 into the CNS.

To summarize, this review has assessed the so far documented evidence for the neuroinvasive potential of SARS-CoV-2. These data have provided strong support for the infection of CNS and shed light on the association of neurological involvement with the lethality of SARS-CoV-2 infection. Awareness of the neuroinvasive potential of SARS-CoV-2 has important guiding significance for the prevention, treatment, and prognosis of SARS-CoV-2 infection.

Exploring the active compounds of traditional Mongolian medicine in intervention of novel coronavirus (COVID-19) based on molecular docking method

Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? European review for medical and pharmacological sciences

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Response to Commentary on "The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients

COVID-19: Fever syndrome and neurological symptoms in a neonate

Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Potential neurological symptoms of COVID-19

Neurologic Involvement in COVID-19: Radiologists' Perspective

Neurological associations of COVID-19

Lifting the mask on neurological manifestations of COVID-19

Brain MRI Findings in Patients in the Intensive Care Unit with COVID-19 Infection

First Case of 2019 Novel Coronavirus Disease with Encephalitis

SARS-CoV-2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID-19 Encephalitis

10 Wochen alter Säugling mit Sepsisverdacht und SARS-CoV-2-Nachweis in Liquor und Rachen [Suspected sepsis in a 10-week-old infant and SARS-CoV-2 detection in cerebrospinal fluid and pharynx

Epub ahead of print

Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study

First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease

Allograft infiltration and meningoencephalitis by SARS-CoV-2 in a pancreas-kidney transplant recipient

COVID-19 infection recurrence presenting with meningoencephalitis. 29. New Microbes New Infect

A First Case of Acute Cerebellitis Associated with Coronavirus Disease (COVID-19): a Case Report and Literature Review

Headache and impaired consciousness level associated with SARS-CoV-2 in CSF: A case report

Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid

COVID-19 meningitis without pulmonary involvement with positive cerebrospinal fluid PCR

Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019

Neurologic Features in Severe SARS-CoV-2 Infection

Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic

Patients with COVID-19 and neurological manifestations show undetectable SARS-CoV-2 RNA levels in the cerebrospinal fluid

Coronavirus disease 2019 associated with aggressive neurological and mental abnormalities confirmed based on This article is protected by copyright. All rights reserved. Accepted Article cerebrospinal fluid antibodies: A case report

First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder

Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model bioRxiv 2020.06.25.169946

Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement

Encephalitis as a clinical manifestation of COVID-19

Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive

Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage

Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology

Cerebral Microvascular Injury in Severe COVID-19

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series

Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy

Postmortem examination of patients with COVID-19

Neuropathologic features of four autopsied COVID-19 patients

Neuropathological Findings in Two Patients with Fatal COVID-19

First ultrastructural autoptic findings of SARS -Cov-2 in olfactory pathways and brainstem

Neuropathological Features of Covid-19

Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system

Multiorgan and Renal Tropism of SARS-CoV-2

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study

Fatal central nervous system co-infection with SARS-CoV-2 and tuberculosis in a healthy child

Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2

SARS-CoV-2 targets neurons of 3D human brain organoids

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques

A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection

Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease

K18-hACE2 mice develop respiratory disease resembling severe COVID-19

SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for reverse zoonosis to New World rodents

Brain autopsies in fatal COVID-19 and postulated pathophysiology: more puzzling than a Rubik's cube

Encephalitic syndrome and anosmia in COVID-19: do these clinical presentations really reflect SARS-CoV-2 neurotropism? A theory based on the review of 25 COVID-19 cases

Potential neuroinvasive pathways of SARS-CoV-2: Deciphering the spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19)

The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in vitro models of the human blood-brain barrier

Cytokine release syndrome-associated encephalopathy in patients with COVID-19

Anosmia and olfactory tract neuropathy in a case of COVID-19

Brain Imaging of Patients with COVID-19: Findings at an Academic Institution during the Height of the Outbreak

Clinical Characteristics and Risk Factors for Disease Severity and Death in Patients With Coronavirus Disease

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Neurologic complications of coronavirus infections

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Clinical features of patients infected with 2019 novel This article is protected by copyright. All rights reserved

Brainstem involvement and respiratory failure in COVID-19

This research was partially by National Natural Science Foundation of China (General Program, 81871014).